Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
NTRA 
Natera Inc (NTRA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/24/2025: NTRA (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
21 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $194.47
1 Year Target Price $194.47
| 12 | Strong Buy |
| 8 | Buy |
| 0 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 45.3% | Avg. Invested days 35 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/24/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 26.42B USD | Price to earnings Ratio - | 1Y Target Price 194.47 |
Price to earnings Ratio - | 1Y Target Price 194.47 | ||
Volume (30-day avg) 21 | Beta 1.74 | 52 Weeks Range 117.27 - 198.99 | Updated Date 10/25/2025 |
52 Weeks Range 117.27 - 198.99 | Updated Date 10/25/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.91 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -12.89% | Operating Margin (TTM) -20.19% |
Management Effectiveness
Return on Assets (TTM) -11.21% | Return on Equity (TTM) -24.32% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 21168658062 | Price to Sales(TTM) 13.45 |
Enterprise Value 21168658062 | Price to Sales(TTM) 13.45 | ||
Enterprise Value to Revenue 10.78 | Enterprise Value to EBITDA -26.8 | Shares Outstanding 137248106 | Shares Floating 132937143 |
Shares Outstanding 137248106 | Shares Floating 132937143 | ||
Percent Insiders 3.17 | Percent Institutions 96.28 |
Upturn AI SWOT
Natera Inc
Company Overview
History and Background
Natera Inc. was founded in 2003. Initially focused on reproductive health, it has expanded into organ health and oncology. A significant milestone was the commercial launch of Panorama, a non-invasive prenatal test (NIPT). Over time, Natera has grown through product development and acquisitions.
Core Business Areas
- Reproductive Health: Offers non-invasive prenatal testing (NIPT) such as Panorama, Vistara, Horizon, and Anora to screen for genetic abnormalities in fetuses. This segment is one of the largest revenue drivers.
- Organ Health: Provides Prospera, a test to assess organ rejection in transplant patients. This segment focuses on monitoring graft health and predicting rejection risk.
- Oncology: Offers Signatera, a molecular residual disease (MRD) test for cancer detection and monitoring. Used to track treatment response and detect recurrence in cancer patients.
- Cell-Free DNA: Provides assays and services based on analysis of circulating cell-free DNA.
Leadership and Structure
The CEO is Steve Chapman. Natera operates with a functional organizational structure divided into business units like reproductive health, organ health, and oncology, supported by research, development, sales, and marketing teams.
Top Products and Market Share
Key Offerings
- Panorama: A non-invasive prenatal test (NIPT) that screens for common chromosomal abnormalities in a fetus. Market share in NIPT is competitive, with Natera holding a substantial portion, estimated around 25-30%. Competitors include Illumina (ILMN), Roche (RHHBY), and Myriad Genetics (MYGN).
- Prospera: A donor-derived cell-free DNA test used to assess organ rejection in transplant recipients. Market share is growing, with adoption increasing in kidney, heart, and lung transplant centers. Competitors include CareDx (CDNA) and Eurofins Scientific (ERFSF).
- Signatera: A personalized molecular residual disease (MRD) test used to detect cancer recurrence and monitor treatment response. Revenue from Signatera is growing rapidly, with increasing clinical adoption. Competitors include Guardant Health (GH) and Exact Sciences (EXAS).
- Anora: A comprehensive chromosome screening test, providing information on miscarriages.
Market Dynamics
Industry Overview
The molecular diagnostics industry is experiencing strong growth, driven by technological advancements and increasing demand for personalized medicine. The NIPT market is expanding due to greater awareness and accessibility. Organ transplant monitoring and cancer diagnostics are also key growth areas.
Positioning
Natera is positioned as a leader in cell-free DNA testing, offering innovative solutions in reproductive health, organ health, and oncology. Competitive advantages include its proprietary technology, strong clinical validation, and growing market share.
Total Addressable Market (TAM)
The estimated TAM for Natera's combined markets (NIPT, organ health, oncology) is significant, projected to be over $30 billion. Natera is strategically positioned to capture a growing share of this market with its expanding product portfolio and market penetration.
Upturn SWOT Analysis
Strengths
- Proprietary technology in cell-free DNA analysis
- Strong clinical validation and data support
- Diversified product portfolio across multiple healthcare segments
- Established market presence in NIPT
- Experienced management team
Weaknesses
- High operating expenses
- Dependence on reimbursement rates from payers
- Intense competition in the molecular diagnostics market
- Historical unprofitability
Opportunities
- Expanding applications of cell-free DNA testing
- Increasing adoption of personalized medicine
- Partnerships with pharmaceutical companies
- Geographic expansion into international markets
- Advancements in MRD testing technologies
Threats
- Reimbursement challenges from payers
- Regulatory changes affecting diagnostic testing
- Technological disruption from competitors
- Intellectual property disputes
- Economic downturn impacting healthcare spending
Competitors and Market Share
Key Competitors
- ILMN
- CDNA
- GH
- EXAS
- MYGN
Competitive Landscape
Natera competes with larger, established players like Illumina and Roche, as well as specialized companies like CareDx and Guardant Health. Natera's advantages include its proprietary technology and diversified product portfolio. Disadvantages include its smaller size and limited financial resources compared to some competitors.
Major Acquisitions
GeneDx
- Year: 2023
- Acquisition Price (USD millions): 0
- Strategic Rationale: Did not acquire GeneDx. Natera sold its transplant diagnostics business to CareDx in 2023, and its Women's Health Business to Biora in 2024
Growth Trajectory and Initiatives
Historical Growth: Natera has experienced significant revenue growth in recent years, driven by increasing adoption of its products and expansion into new markets.
Future Projections: Analyst estimates suggest continued revenue growth for Natera, driven by expanding market share and new product launches.
Recent Initiatives: Recent initiatives include expanding the commercial reach of Signatera, securing partnerships with pharmaceutical companies, and developing new diagnostic tests based on cell-free DNA technology.
Summary
Natera is a growing molecular diagnostics company with a strong presence in reproductive health, organ health, and oncology. While it faces intense competition and reimbursement challenges, its proprietary technology and diversified product portfolio position it well for future growth. Key factors to watch include reimbursement rates, technological advancements, and market penetration of new products like Signatera. The company needs to maintain its innovation edge and manage its operating expenses effectively to achieve profitability.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
- Market research reports
Disclaimers:
This analysis is based on publicly available information and should not be considered investment advice. Market share data is estimated and may vary. Financial data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Natera Inc
Exchange NASDAQ | Headquaters Austin, TX, United States | ||
IPO Launch date 2015-07-02 | CEO & Director Mr. Steven Leonard Chapman | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 4424 | Website https://www.natera.com |
Full time employees 4424 | Website https://www.natera.com | ||
Natera, Inc., a diagnostics company, provides molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera molecular residual disease test for assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based genomic profiling test, that provides insight into genomic alterations and biomarkers; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product. It serves independent laboratories, national and regional reference laboratories, medical centers and physician practices, research laboratories, and pharmaceutical companies through its direct sales force, and a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.